Meccellis Biotech Granted CE Mark for Breast Reconstruction Products

Meccellis Biotech received the CE Mark for its range of biological matrix products used in abdominal wall and breast reconstruction surgery.

The CE Mark for the products was previously withdrawn. The renewal allows its client, Surgical Innovations, to resume selling the Cellis product range.

The CE Mark covers a range of products that are due to be launched in the UK next year.